FindTrial
Sign In

Efficacy, cardiovascular benefits and safety of second-line anti-diabetic drugs in patients with type 2 diabetes: a real world based pragmatic clinical trial

Efficacy, cardiovascular benefits and safety of second-line anti-diabetic drugs in patients with type 2 diabetes: a real world based pragmatic clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036600
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

1:glimepiride
2:sitagliptin
3:liraglutide
4:dapaglifozin

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes; 2. Aged >= 45 years; 3. Metformin monotherapy for 3 months; 4. Suboptimal glycemic control; 5. With or without history of CVD; 6. Long term membership in Shanghai sixth peoples hospital.

Exclusion criteria

Exclusion criteria: 1. Congestive heart failure; 2. History of pancreatis; 3. History of cancer; 4. Liver cirrhosis; 5. Severe anemia; 6. CKD stage 4 or 5; 7. Pregnancy.

Design outcomes

Primary

MeasureTime frame
hemoglobin A1c;—

Secondary

MeasureTime frame
systolic blood pressure;LDL cholesterol;Body mass index;—

Countries

China

Contacts

Public ContactYun Shen

Shanghai Sixth People's Hospital

xiaodonkey@outlook.com.cn+86 18930170406

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026